Senzime AB (SEZI)

Stockholm
Currency in SEK
4.8800
+0.1100(+2.31%)
Real-time Data·
SEZI Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
SEZI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.73004.8850
52 wk Range
3.60009.6000
Key Statistics
Edit
Prev. Close
4.77
Open
4.75
Day's Range
4.73-4.885
52 wk Range
3.6-9.6
Volume
61.2K
Average Volume (3m)
189.44K
1-Year Change
-28.59%
Book Value / Share
2.3
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SEZI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Senzime Company Profile

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It provides TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system and related digital hub for data transmission to hospital electronic patient journals; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.

Senzime AB Earnings Call Summary for Q1/2025

  • Net sales surged 94% in Q1 2025, stock jumped 8.09% post-earnings
  • Company targets 115-130 million SEK revenue for 2025, aims to become 1 billion SEK company long-term
  • Expansion into Japan and South Korea underway, focus on scientific validation and AI-assisted tools
  • EBITDA remains negative at -$8.84M but trending towards profitability; gross margin improved year-over-year
  • CEO emphasizes mission to make technology standard of care globally, commits to winning 'by science'
Last Updated: 22-04-2025, 05:34 pm
Read Full Transcript

Compare SEZI to Peers and Sector

Metrics to compare
SEZI
Peers
Sector
Relationship
P/E Ratio
−5.1x−15.1x−0.5x
PEG Ratio
−0.26−0.240.00
Price/Book
2.1x5.0x2.6x
Price / LTM Sales
9.1x4.7x3.0x
Upside (Analyst Target)
146.2%0.0%52.7%
Fair Value Upside
Unlock8.8%7.6%Unlock

Earnings

Latest Release
Apr 22, 2025
EPS / Forecast
-0.26 / -0.20
Revenue / Forecast
23.50M / 23.10M
EPS Revisions
Last 90 days

FAQ

What Is the Senzime (SEZI) Stock Price Today?

The Senzime stock price today is 4.88.

What Stock Exchange Does Senzime Trade On?

Senzime is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Senzime?

The stock symbol for Senzime is "SEZI."

What Is the Senzime Market Cap?

As of today, Senzime market cap is 649.42M.

What Is Senzime's Earnings Per Share (TTM)?

The Senzime EPS (TTM) is -1.00.

When Is the Next Senzime Earnings Date?

Senzime will release its next earnings report on 21 Aug 2025.

From a Technical Analysis Perspective, Is SEZI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.